{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:06:09Z","timestamp":1794265569695,"version":"4.9.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite decades of research very few vaccine-adjuvants have received FDA approval. Two fundamental challenges plague clinical translation of vaccine-adjuvants: reducing acute toxicities that result from systemic diffusion of many soluble adjuvants, and delivering multiple adjuvants at the same time to mimic the synergistic immune-stimulation of pathogens, while being safe. In order to address these barriers, we evaluated combinations of four clinically relevant immune-agonists, specifically Toll-like receptor (TLR) ligands, using biodegradable, polymer microparticles. We tested them alone and in combinations of 2 or 3, for a total of 10 unique conditions. We evaluated primary bone-marrow-derived Dendritic Cell phenotypes and functionality, and identified several synergistic combinations. We picked a dual and a triple adjuvant combination, TLR4\/TLR9 and TLR4\/TLR7\/TLR9, for further evaluation and found that both combinations promoted antigen cross-presentation <jats:italic>in vitro<\/jats:italic>. Studies in mice using the model antigen Ovalbumin, showed that both combinations enhanced lymph node germinal center and T follicular helper cell responses. The triple adjuvant combination showed increased antigen-specific antibody titer with an overall balanced Th1\/Th2 response, while the dual combination promoted Th1-polarized IgG responses. Our results show how polymeric particulate-carriers can be adopted to safely deliver combinatorial adjuvants and selectively synergize specific types of immune responses for vaccine applications.<\/jats:p>","DOI":"10.1038\/s41598-017-02804-y","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T10:20:34Z","timestamp":1495621234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses"],"prefix":"10.1038","volume":"7","author":[{"given":"Ranjna","family":"Madan-Lala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallab","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnendu","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"2804_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.coi.2010.04.004","volume":"22","author":"ML Mbow","year":"2010","unstructured":"Mbow, M. L., De Gregorio, E., Valiante, N. M. & Rappuoli, R. New adjuvants for human vaccines. Curr. Opin. Immunol. \n                           22, 411\u2013416, doi:10.1016\/j.coi.2010.04.004 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"2804_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.f.1774","volume":"14","author":"V Appay","year":"2008","unstructured":"Appay, V., Douek, D. C. & Price, D. A. CD8+ T cell efficacy in vaccination and disease. Nat. Med. \n                           14, 623\u2013628, doi:10.1038\/nm.f.1774 (2008).","journal-title":"Nat. Med."},{"key":"2804_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science \n                           334, 475\u2013480, doi:10.1126\/science.1211548 (2011).","journal-title":"Science"},{"key":"2804_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/35021239","volume":"406","author":"RA Seder","year":"2000","unstructured":"Seder, R. A. & Hill, A. V. Vaccines against intracellular infections requiring cellular immunity. Nature \n                           406, 793\u2013798, doi:10.1038\/35021239 (2000).","journal-title":"Nature"},{"key":"2804_CR5","doi-asserted-by":"publisher","first-page":"e1003001","DOI":"10.1371\/journal.ppat.1003001","volume":"8","author":"C Rueckert","year":"2012","unstructured":"Rueckert, C. & Guzman, C. A. Vaccines: from empirical development to rational design. PLoS Pathog. \n                           8, e1003001, doi:10.1371\/journal.ppat.1003001 (2012).","journal-title":"PLoS Pathog."},{"key":"2804_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature \n                           392, 245\u2013252, doi:10.1038\/32588 (1998).","journal-title":"Nature"},{"key":"2804_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/3-540-32636-7","volume":"311","author":"RM Steinman","year":"2006","unstructured":"Steinman, R. M. & Hemmi, H. Dendritic cells: translating innate to adaptive immunity. Current topics in microbiology and immunology \n                           311, 17\u201358, doi:10.1007\/3-540-32636-7 (2006).","journal-title":"Current topics in microbiology and immunology"},{"key":"2804_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.immuni.2014.04.016","volume":"40","author":"A Mildner","year":"2014","unstructured":"Mildner, A. & Jung, S. Development and function of dendritic cell subsets. Immunity \n                           40, 642\u2013656, doi:10.1016\/j.immuni.2014.04.016 (2014).","journal-title":"Immunity"},{"key":"2804_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.0105-2896.2004.00144.x","volume":"199","author":"B Pulendran","year":"2004","unstructured":"Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. \n                           199, 227\u2013250, doi:10.1111\/j.0105-2896.2004.00144.x (2004).","journal-title":"Immunol. Rev."},{"key":"2804_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08830185.2010.529976","volume":"30","author":"H Kumar","year":"2011","unstructured":"Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. \n                           30, 16\u201334, doi:10.3109\/08830185.2010.529976 (2011).","journal-title":"Int. Rev. Immunol."},{"key":"2804_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/79734","volume":"1","author":"M Moser","year":"2000","unstructured":"Moser, M. & Murphy, K. M. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. \n                           1, 199\u2013205, doi:10.1038\/79734 (2000).","journal-title":"Nat. Immunol."},{"key":"2804_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.coi.2005.02.007","volume":"17","author":"T Kawai","year":"2005","unstructured":"Kawai, T. & Akira, S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. \n                           17, 338\u2013344, doi:10.1016\/j.coi.2005.02.007 (2005).","journal-title":"Curr. Opin. Immunol."},{"key":"2804_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. \n                           11, 373\u2013384, doi:10.1038\/ni.1863 (2010).","journal-title":"Nat. Immunol."},{"key":"2804_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","volume":"21","author":"K Takeda","year":"2003","unstructured":"Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annual review of immunology \n                           21, 335\u2013376, doi:10.1146\/annurev.immunol.21.120601.141126 (2003).","journal-title":"Annual review of immunology"},{"key":"2804_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell \n                           124, 783\u2013801, doi:10.1016\/j.cell.2006.02.015 (2006).","journal-title":"Cell"},{"key":"2804_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. \n                           5, 461, doi:10.3389\/fimmu.2014.00461 (2014).","journal-title":"Front. Immunol."},{"key":"2804_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/35074106","volume":"410","author":"F Hayashi","year":"2001","unstructured":"Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature \n                           410, 1099\u20131103, doi:10.1038\/35074106 (2001).","journal-title":"Nature"},{"key":"2804_CR18","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.1074\/jbc.274.16.10689","volume":"274","author":"JC Chow","year":"1999","unstructured":"Chow, J. C., Young, D. W., Golenbock, D. T., Christ, W. J. & Gusovsky, F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. \n                           274, 10689\u201310692, doi:10.1074\/jbc.274.16.10689 (1999).","journal-title":"J. Biol. Chem."},{"key":"2804_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","volume":"413","author":"L Alexopoulou","year":"2001","unstructured":"Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature \n                           413, 732\u2013738, doi:10.1038\/35099560 (2001).","journal-title":"Nature"},{"key":"2804_CR20","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"F Heil","year":"2004","unstructured":"Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science \n                           303, 1526\u20131529, doi:10.1126\/science.1093620 (2004).","journal-title":"Science"},{"key":"2804_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/35047123","volume":"408","author":"H Hemmi","year":"2000","unstructured":"Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature \n                           408, 740\u2013745, doi:10.1038\/35047123 (2000).","journal-title":"Nature"},{"key":"2804_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","volume":"239","author":"MS Duthie","year":"2011","unstructured":"Duthie, M. S., Windish, H. P., Fox, C. B. & Reed, S. G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. \n                           239, 178\u2013196, doi:10.1111\/j.1600-065X.2010.00978.x (2011).","journal-title":"Immunol. Rev."},{"key":"2804_CR23","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/eji.200323919","volume":"33","author":"K Schwarz","year":"2003","unstructured":"Schwarz, K. et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. \n                           33, 1465\u20131470, doi:10.1002\/eji.200323919 (2003).","journal-title":"Eur. J. Immunol."},{"key":"2804_CR24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1086\/653499","volume":"202","author":"D Mitchell","year":"2010","unstructured":"Mitchell, D. et al. Dual stimulation of MyD88-dependent Toll-like receptors induces synergistically enhanced production of inflammatory cytokines in murine bone marrow-derived dendritic cells. J. Infect. Dis. \n                           202, 318\u2013329, doi:10.1086\/653499 (2010).","journal-title":"J. Infect. Dis."},{"key":"2804_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/vaccines2020323","volume":"2","author":"DN Toussi","year":"2014","unstructured":"Toussi, D. N. & Massari, P. Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines (Basel) \n                           2, 323\u2013353, doi:10.3390\/vaccines2020323 (2014).","journal-title":"Vaccines (Basel)"},{"key":"2804_CR26","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.4049\/jimmunol.1101764","volume":"188","author":"E Caproni","year":"2012","unstructured":"Caproni, E. et al. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J. Immunol. \n                           188, 3088\u20133098, doi:10.4049\/jimmunol.1101764 (2012).","journal-title":"J. Immunol."},{"key":"2804_CR27","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","volume":"65","author":"CR Casella","year":"2008","unstructured":"Casella, C. R. & Mitchell, T. C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cellular and molecular life sciences: CMLS \n                           65, 3231\u20133240, doi:10.1007\/s00018-008-8228-6 (2008).","journal-title":"Cellular and molecular life sciences: CMLS"},{"key":"2804_CR28","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","volume":"4","author":"JR Baldridge","year":"2004","unstructured":"Baldridge, J. R. et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. \n                           4, 1129\u20131138, doi:10.1517\/14712598.4.7.1129 (2004).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2804_CR29","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1126\/science.1138963","volume":"316","author":"V Mata-Haro","year":"2007","unstructured":"Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science \n                           316, 1628\u20131632, doi:10.1126\/science.1138963 (2007).","journal-title":"Science"},{"key":"2804_CR30","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/infdis\/jit365","volume":"208","author":"R Chlibek","year":"2013","unstructured":"Chlibek, R. et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=\u200950 years of age. J. Infect. Dis. \n                           208, 1953\u20131961, doi:10.1093\/infdis\/jit365 (2013).","journal-title":"J. Infect. Dis."},{"key":"2804_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","volume":"3","author":"H Hemmi","year":"2002","unstructured":"Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. \n                           3, 196\u2013200, doi:10.1038\/ni758 (2002).","journal-title":"Nat. Immunol."},{"key":"2804_CR32","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1073\/pnas.0631696100","volume":"100","author":"J Lee","year":"2003","unstructured":"Lee, J. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA \n                           100, 6646\u20136651, doi:10.1073\/pnas.0631696100 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2804_CR33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1586\/14760584.2013.811208","volume":"12","author":"JP Vasilakos","year":"2013","unstructured":"Vasilakos, J. P. & Tomai, M. A. The use of Toll-like receptor 7\/8 agonists as vaccine adjuvants. Expert Rev Vaccines \n                           12, 809\u2013819, doi:10.1586\/14760584.2013.811208 (2013).","journal-title":"Expert Rev Vaccines"},{"key":"2804_CR34","first-page":"9","volume":"4","author":"M Shackleton","year":"2004","unstructured":"Shackleton, M. et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun \n                           4, 9 (2004).","journal-title":"Cancer Immun"},{"key":"2804_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4049\/jimmunol.181.1.776","volume":"181","author":"S Adams","year":"2008","unstructured":"Adams, S. et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. \n                           181, 776\u2013784, doi:10.4049\/jimmunol.181.1.776 (2008).","journal-title":"J. Immunol."},{"key":"2804_CR36","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1086\/515343","volume":"178","author":"D Goldstein","year":"1998","unstructured":"Goldstein, D. et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J. Infect. Dis. \n                           178, 858\u2013861, doi:10.1086\/jid.1998.178.issue-3 (1998).","journal-title":"J. Infect. Dis."},{"key":"2804_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","volume":"20","author":"AM Krieg","year":"2002","unstructured":"Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. \n                           20, 709\u2013760, doi:10.1146\/annurev.immunol.20.100301.064842 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"2804_CR38","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.4049\/jimmunol.1000768","volume":"185","author":"SL Demento","year":"2010","unstructured":"Demento, S. L. et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J. Immunol. \n                           185, 2989\u20132997, doi:10.4049\/jimmunol.1000768 (2010).","journal-title":"J. Immunol."},{"key":"2804_CR39","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","volume":"22","author":"DM Klinman","year":"2004","unstructured":"Klinman, D. M., Xie, H., Little, S. F., Currie, D. & Ivins, B. E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine \n                           22, 2881\u20132886, doi:10.1016\/j.vaccine.2003.12.020 (2004).","journal-title":"Vaccine"},{"key":"2804_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.10.174","volume":"10","author":"C Bode","year":"2011","unstructured":"Bode, C., Zhao, G., Steinhagen, F., Kinjo, T. & Klinman, D. M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines \n                           10, 499\u2013511, doi:10.1586\/erv.10.174 (2011).","journal-title":"Expert Rev Vaccines"},{"key":"2804_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nri1329","volume":"4","author":"DM Klinman","year":"2004","unstructured":"Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. \n                           4, 249\u2013258, doi:10.1038\/nri1329 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"2804_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/eji.200324032","volume":"34","author":"J Vollmer","year":"2004","unstructured":"Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. \n                           34, 251\u2013262, doi:10.1002\/eji.200324032 (2004).","journal-title":"Eur. J. Immunol."},{"key":"2804_CR43","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/ni1223","volume":"6","author":"G Napolitani","year":"2005","unstructured":"Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F. & Lanzavecchia, A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. \n                           6, 769\u2013776, doi:10.1038\/ni1223 (2005).","journal-title":"Nat. Immunol."},{"key":"2804_CR44","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/S0264-410X(99)00062-6","volume":"17","author":"A Moore","year":"1999","unstructured":"Moore, A., McCarthy, L. & Mills, K. H. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine \n                           17, 2517\u20132527, doi:10.1016\/S0264-410X(99)00062-6 (1999).","journal-title":"Vaccine"},{"key":"2804_CR45","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.4049\/jimmunol.1000238","volume":"185","author":"VS Raman","year":"2010","unstructured":"Raman, V. S. et al. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J. Immunol. \n                           185, 1701\u20131710, doi:10.4049\/jimmunol.1000238 (2010).","journal-title":"J. Immunol."},{"key":"2804_CR46","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.4049\/jimmunol.178.2.1164","volume":"178","author":"A Bagchi","year":"2007","unstructured":"Bagchi, A. et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. \n                           178, 1164\u20131171, doi:10.4049\/jimmunol.178.2.1164 (2007).","journal-title":"J. Immunol."},{"key":"2804_CR47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1182\/blood-2005-10-4015","volume":"108","author":"T Warger","year":"2006","unstructured":"Warger, T. et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood \n                           108, 544\u2013550, doi:10.1182\/blood-2005-10-4015 (2006).","journal-title":"Blood"},{"key":"2804_CR48","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1189\/jlb.0808503","volume":"85","author":"SM Makela","year":"2009","unstructured":"Makela, S. M., Strengell, M., Pietila, T. E., Osterlund, P. & Julkunen, I. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J. Leukoc. Biol. \n                           85, 664\u2013672, doi:10.1189\/jlb.0808503 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"2804_CR49","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1172\/JCI79915","volume":"125","author":"MC Hanson","year":"2015","unstructured":"Hanson, M. C. et al. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J. Clin. Invest. \n                           125, 2532\u20132546, doi:10.1172\/JCI79915 (2015).","journal-title":"J. Clin. Invest."},{"key":"2804_CR50","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1016\/j.biomaterials.2011.03.067","volume":"32","author":"B Kwong","year":"2011","unstructured":"Kwong, B., Liu, H. & Irvine, D. J. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials \n                           32, 5134\u20135147, doi:10.1016\/j.biomaterials.2011.03.067 (2011).","journal-title":"Biomaterials"},{"key":"2804_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cncr.10631","volume":"95","author":"O Eton","year":"2002","unstructured":"Eton, O. et al. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer \n                           95, 127\u2013134, doi:10.1002\/cncr.10631 (2002).","journal-title":"Cancer"},{"key":"2804_CR52","first-page":"3983","volume":"5","author":"JE Portielje","year":"1999","unstructured":"Portielje, J. E. et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. \n                           5, 3983\u20133989 (1999).","journal-title":"Clin. Cancer Res."},{"key":"2804_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1586\/ecp.11.5","volume":"4","author":"AL Engel","year":"2011","unstructured":"Engel, A. L., Holt, G. E. & Lu, H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev. Clin. Pharmacol \n                           4, 275\u2013289, doi:10.1586\/ecp.11.5 (2011).","journal-title":"Expert Rev. Clin. Pharmacol"},{"key":"2804_CR54","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.V96.4.1465.h8001465_1465_1473","volume":"96","author":"WE Carson","year":"2000","unstructured":"Carson, W. E. et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood \n                           96, 1465\u20131473 (2000).","journal-title":"Blood"},{"key":"2804_CR55","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09737","volume":"470","author":"SP Kasturi","year":"2011","unstructured":"Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature \n                           470, 543\u2013547, doi:10.1038\/nature09737 (2011).","journal-title":"Nature"},{"key":"2804_CR56","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/nbt.3371","volume":"33","author":"GM Lynn","year":"2015","unstructured":"Lynn, G. M. et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. \n                           33, 1201\u20131210, doi:10.1038\/nbt.3371 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2804_CR57","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","volume":"32","author":"PO Ilyinskii","year":"2014","unstructured":"Ilyinskii, P. O. et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine \n                           32, 2882\u20132895, doi:10.1016\/j.vaccine.2014.02.027 (2014).","journal-title":"Vaccine"},{"key":"2804_CR58","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1073\/pnas.1112648109","volume":"109","author":"JJ Moon","year":"2012","unstructured":"Moon, J. J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. USA \n                           109, 1080\u20131085, doi:10.1073\/pnas.1112648109 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2804_CR59","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier, F. et al. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release \n                           161, 505\u2013522, doi:10.1016\/j.jconrel.2012.01.043 (2012).","journal-title":"J. Control. Release"},{"key":"2804_CR60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","volume":"55","author":"J Panyam","year":"2003","unstructured":"Panyam, J. & Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev \n                           55, 329\u2013347, doi:10.1016\/S0169-409X(02)00228-4 (2003).","journal-title":"Adv Drug Deliv Rev"},{"key":"2804_CR61","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.addr.2007.05.017","volume":"60","author":"LJ Peek","year":"2008","unstructured":"Peek, L. J., Middaugh, C. R. & Berkland, C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev \n                           60, 915\u2013928, doi:10.1016\/j.addr.2007.05.017 (2008).","journal-title":"Adv Drug Deliv Rev"},{"key":"2804_CR62","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1016\/j.biomaterials.2005.03.043","volume":"26","author":"SP Kasturi","year":"2005","unstructured":"Kasturi, S. P., Sachaphibulkij, K. & Roy, K. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials \n                           26, 6375\u20136385, doi:10.1016\/j.biomaterials.2005.03.043 (2005).","journal-title":"Biomaterials"},{"key":"2804_CR63","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jconrel.2006.04.006","volume":"113","author":"S Pai Kasturi","year":"2006","unstructured":"Pai Kasturi, S. et al. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. Journal of controlled release: official journal of the Controlled Release Society \n                           113, 261\u2013270, doi:10.1016\/j.jconrel.2006.04.006 (2006).","journal-title":"Journal of controlled release: official journal of the Controlled Release Society"},{"key":"2804_CR64","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1016\/j.biomaterials.2014.03.039","volume":"35","author":"P Pradhan","year":"2014","unstructured":"Pradhan, P. et al. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1\/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials \n                           35, 5491\u20135504, doi:10.1016\/j.biomaterials.2014.03.039 (2014).","journal-title":"Biomaterials"},{"key":"2804_CR65","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nmat3775","volume":"12","author":"DJ Irvine","year":"2013","unstructured":"Irvine, D. J., Swartz, M. A. & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nat Mater \n                           12, 978\u2013990, doi:10.1038\/nmat3775 (2013).","journal-title":"Nat Mater"},{"key":"2804_CR66","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.addr.2004.09.008","volume":"57","author":"T Storni","year":"2005","unstructured":"Storni, T., Kundig, T. M., Senti, G. & Johansen, P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev \n                           57, 333\u2013355, doi:10.1016\/j.addr.2004.09.008 (2005).","journal-title":"Adv Drug Deliv Rev"},{"key":"2804_CR67","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. \n                           3, 133\u2013146, doi:10.1038\/nri1001 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"2804_CR68","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1172\/JCI39293","volume":"120","author":"Q Zhu","year":"2010","unstructured":"Zhu, Q. et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Invest. \n                           120, 607\u2013616, doi:10.1172\/JCI39293 (2010).","journal-title":"J. Clin. Invest."},{"key":"2804_CR69","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1471-230X-11-64","volume":"11","author":"C Maldonado Galdeano","year":"2011","unstructured":"Maldonado Galdeano, C. et al. Impact of a probiotic fermented milk in the gut ecosystem and in the systemic immunity using a non-severe protein-energy-malnutrition model in mice. BMC Gastroenterol. \n                           11, 64, doi:10.1186\/1471-230X-11-64 (2011).","journal-title":"BMC Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02804-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02804-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T04:41:26Z","timestamp":1671770486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02804-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-02804-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]},"assertion":[{"value":"22 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2530"}}